OncoMatch/Clinical Trials/NCT07283900
Ascorbate in Myelodysplastic Syndrome
Is NCT07283900 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including High-dose ascorbate and Azacitidine for myelodysplastic syndromes.
Treatment: High-dose ascorbate · Azacitidine — This is an open-label, phase II clinical trial with safety run-in evaluating the safety, tolerability, and efficacy of IV HDA in combination with azacitidine for participants with MDS.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage MODERATE HIGH, HIGH, VERY HIGH (Molecular International Prognostic Scoring System (IPSS-M))
Higher-risk MDS per the Molecular International Prognostic Scoring System (IPSS-M) - Moderate High, High, or Very High risk categories.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: MDS-directed therapy
Exception: ≤ 1 prior cycle of azacitidine, decitabine, or oral decitabine-cedazuridine; or prior use of ESA, luspatercept, or imetelstat. Prior hydroxyurea use is allowed but continuation beyond Cycle 1 requires PI approval.
No prior MDS-directed therapy, except: ≤ 1 prior cycle of azacitidine, decitabine, or oral decitabine-cedazuridine; or prior use of ESA, luspatercept, or imetelstat. Prior hydroxyurea use is allowed but continuation beyond Cycle 1 requires PI approval.
Lab requirements
Kidney function
creatinine clearance >45 ml/min
Liver function
total bilirubin ≤1.5 × uln; alt and ast ≤3 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Iowa · Iowa City, Iowa
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07283900 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MDS-directed therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage MODERATE HIGH or HIGH or VERY HIGH is required.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages